LIMK1 and cancer: Correspondingly, LIMK activity may be associated with a wide variety of pathologies, including hypertension (Morales-Quinones et al., 2020), aneurysm (Akagawa et al., 2006), erectile dysfunction (Park et al., 2021), glaucoma (Harrison et al., 2015), cancer resistance to microtubule-targeting chemotherapy (Acevedo et al., 2007; Mardilovich et al., 2015), pain (Yang et al., 2017), neuronal diseases (Ben Zablah et al., 2021), neurofibromatosis (Petrilli et al., 2014), etc. At the same time, its inhibition has emerged as a prospective therapeutic target for some of these diverse diseases.